IPN Ipsen SA

Ipsen S.A. publishes its 2024 consolidated financial statements

Ipsen S.A. publishes its 2024 consolidated financial statements

Ipsen S.A. - 2024 Consolidated Financial Statements

Attachment



EN
21/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE

Ipsen announces issuance of €500 million inaugural Rated Public Bond

Ipsen announces issuance of €500 million inaugural Rated Public Bond Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today announced the successful completion of its inaugural Rated Public Bond of €500 million with a coupon of 3.875%, maturing in March 2032. Following the disclosure of the Investment Grade ratings with BBB- from S&P and Baa3 from Moody’s, both with a stable outlook, this transaction was very well received and largely oversu...

 PRESS RELEASE

Ipsen annonce le succès de son émission obligataire inaugurale notée d...

Ipsen annonce le succès de son émission obligataire inaugurale notée d'un montant de 500 millions d'euros Cette transaction fait suite à l’attribution, par S&P et Moody’s, de notations de crédit ‘Investment Grade’ PARIS, FRANCE, 19 mars 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), groupe biopharmaceutique mondial de spécialité, a annoncé aujourd'hui, le succès de son émission obligataire inaugurale notée de 500 millions d'euros, assortie d'un coupon de 3.875%, et arrivant à échéance en mars 2032. Cette transaction, lancée peu après l’attribution par S&P et Moody’s de notations de crédit ‘...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet

ResearchPool Subscriptions

Get the most out of your insights

Get in touch